Get Premium to unlock powerful stock data
NAS:SPRO (USA)  
Spero Therapeutics Inc logo

Spero Therapeutics Inc

$ 0.94 -0.11 (-10.48%) 10:08 PM EST
P/E:
At Loss
P/B:
0.49
Market Cap:
$ 30.85M
Enterprise V:
$ -84.02M
Volume:
3.25M
Avg Vol (2M):
965.87K
Also Trade In:
Volume:
3.25M
Market Cap $:
30.85M
PE Ratio:
At Loss
Avg Vol (2-Month):
965.87K
Enterprise Value $:
-84.02M
PB Ratio:
0.49
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Spero Therapeutics Inc
NAICS : 325412 SIC : 2834
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Name Current Vs Industry Vs History
Cash-To-Debt 17.19
Equity-to-Asset 0.43
Debt-to-Equity 0.11
Debt-to-EBITDA -0.07
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.24
Distress
Grey
Safe
Beneish M-Score -4.95
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.12
9-Day RSI 34.37
14-Day RSI 27.95
6-1 Month Momentum % -91.23
12-1 Month Momentum % -91.81

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.92
Quick Ratio 1.92
Cash Ratio 1.76

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -23.5

Financials (Next Earnings Date:2022-08-05 Est.)

SPRO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SPRO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 13.025
EPS (TTM) ($) -3.26
Beta 1.8
Volatility % 101.18
14-Day RSI 27.95
14-Day ATR ($) 0.152502
20-Day SMA ($) 1.050365
12-1 Month Momentum % -91.81
52-Week Range ($) 0.8549 - 19.87
Shares Outstanding (Mil) 32.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Spero Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More